All In Biotech

Drug Trial Radar · NCT02145182

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Aug 21, 2014

Primary completion

Nov 22, 2016

Study completion Nov 22, 2016

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
May 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Conditions

  • Delayed Graft Function

Interventions

  • EculizumabDrug

    Eculizumab is a complement component 5 inhibitor.

  • PlaceboDrug

    0.9% sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplantTime frame: First 7 days post transplantation

Locations

78 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Tampa, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Livingston, New Jersey

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Charleston, South Carolina

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Westmead, New South Wales, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, Brazil

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Toronto, Ontario, Canada

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.